摘要
目的 探究信迪利单抗联合紫杉醇(白蛋白结合型)、铂类化疗对ⅢB~Ⅳ期肺鳞状细胞癌(LSCC)的临床疗效及其对肿瘤标志物的影响。方法 回顾性分析2021年6月至2023年3月乐山市人民医院收治的87例ⅢB~Ⅳ期LSCC患者的临床资料,根据用药方案不同分为对照组(39例)和观察组(48例),对照组采用紫杉醇(白蛋白结合型)、铂类化疗,观察组在对照组的基础上联合信迪利单抗治疗。对比两组患者治疗12周后的临床疗效、肿瘤标志物、不良反应及生存情况。结果 治疗12周后,观察组的客观缓解率和疾病控制率分别为41.67%和81.25%,高于对照组(20.51%和61.54%),差异具有统计学意义(χ^(2)=4.412,4.185,均P<0.05);观察组癌胚抗原、血清细胞角蛋白19片段21-1、鳞状上皮细胞癌抗原水平[分别为(5.78±1.51) ng·m L^(-1)、(4.34±1.21) ng·m L^(-1)、(16.78±3.45) ng·m L^(-1)]低于对照组[分别为(8.45±1.87) ng·m L^(-1)、(6.02±2.02) ng·m L^(-1)、(25.48±4.31) ng·m L^(-1)],差异具有统计学意义(均P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组的中位无进展生存期(PFS)、中位总生存期(OS)分别为14.09个月和17.59个月,长于对照组(10.82个月和12.88个月),差异具有统计学意义(均P<0.05)。结论 信迪利单抗联合紫杉醇(白蛋白结合型)、铂类化疗对ⅢB~Ⅳ期LSCC的疗效较好,可以改善肿瘤标志物的表达,安全性可控。
Objective To investigate the clinical efficacy of sintilimab combined with paclitaxel(albumin-binding type)and platinum-based chemotherapy for stageⅢB-IV lung squamous cell carcinoma(LSCC)and its impact on tumor markers.Methods Retrospective analysis was conducted for clinical data of 87 patients with stageⅢB-IV LSCC admitted to Leshan People's Hospital from June 2021 to March 2023.These patients were divided into two groups according to the different medication regimens.The patients in the control group(n=39)received paclitaxel(albumin-binding type)and platinum-based chemotherapy while those in the observation group(n=48)received sintilimab in addition.All the patients in both groups were treated for at least 12 weeks and then the clinical efficacy,tumor markers,adverse reactions and survival were compared between the two groups.Results After treatment,the observation group reported higher objective remission rate and disease control rate as compared with the control(41.67%vs 20.51%,81.25%vs 61.54%,P<0.05).Meanwhile,the observation group had lower serum concentrations of carcinoembryonic antigen,cytokeratin 19 fragment and squamous cell carcinoma antigen than the control((5.78±1.51)ng·mL^(-1) vs(8.45±1.87)ng·mL^(-1),(4.34±1.21)ng·mL^(-1) vs(6.02±2.02)ng·mL^(-1),(16.78±3.45)ng·mL^(-1) vs(25.48±4.31)ng·mL^(-1),all P<0.05).No statistical difference was found in adverse reaction rate between the two groups(P>0.05).The median progression-free survival(PFS)and overall survival(OS)in the observation group were 14.09 months and 17.59 months,respectively,which were longer than 10.82 months and 12.88 months in the control(P<0.05).Conclusion Sintilimab combined with paclitaxel(albumin-binding type)and platinum-based chemotherapy can effectively ameliorate the expression of tumor markers and has a good safety profile in patients with stageⅢB-IV LSCC.
作者
何兵
游曼清
魏海龙
He Bing;You Man-qing;Wei Hai-long(Department of Respiratory and Critical Care Medicine,Leshan People's Hospital,Leshan 614000,China)
出处
《中国药物应用与监测》
CAS
2024年第4期364-367,共4页
Chinese Journal of Drug Application and Monitoring
